Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.1%

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s share price traded down 5.1% during mid-day trading on Monday . The company traded as low as $17.38 and last traded at $17.72. 145,191 shares traded hands during trading, a decline of 63% from the average session volume of 394,035 shares. The stock had previously closed at $18.67.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, May 3rd. They set an “overweight” rating and a $34.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, April 23rd. Finally, Evercore ISI boosted their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.

Kiniksa Pharmaceuticals Trading Down 4.1 %

The stock has a market cap of $1.27 billion, a P/E ratio of 159.29 and a beta of 0.38. The stock’s fifty day moving average price is $19.03 and its 200 day moving average price is $19.03.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The firm had revenue of $79.90 million during the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.26% and a net margin of 2.78%. The business’s revenue for the quarter was up 65.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) EPS. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.1 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of KNSA. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals in the 1st quarter worth about $71,000. China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 349.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock valued at $72,000 after acquiring an additional 3,186 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at about $213,000. Bayesian Capital Management LP bought a new position in Kiniksa Pharmaceuticals during the 1st quarter valued at about $222,000. Finally, Victory Capital Management Inc. lifted its stake in Kiniksa Pharmaceuticals by 45.0% during the 4th quarter. Victory Capital Management Inc. now owns 14,653 shares of the company’s stock valued at $257,000 after acquiring an additional 4,547 shares during the period. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.